Significance of KEAP1 mutation in melnaoma cells.
Project/Area Number |
26860891
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Iwate Medical University |
Principal Investigator |
Miura Shinpei 岩手医科大学, 医学部, 助教 (30713226)
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | KEAP1 / NRF2 / CDDP / ドライバー変異 / 悪性黒色腫 / EMT / 薬剤耐性 |
Outline of Final Research Achievements |
We identified KEAP1 inactivation mutation in booth malignant melanoma cell lines and primary tumors. Mutations of the KEAP1 genes related to drug resistance (CDDP and dacarbazine). The ratio of reduced-to-oxidized glutathione (GSH/GSSG) was decreased by treatment with CDDP or DTIC in siNRF2-transfected cells. However, the mutation did not confer the tumorigenicty for xenografts. Theses results suggest that EAP/NRF2 inactivation could not be a driver mutation in melanoma cells.
|
Report
(3 results)
Research Products
(1 results)